Before you start treatment with Dupixent, tell your doctor and pharmacist ... It’s important to note that atopic dermatitis (a type of eczema) may be improved or worsened by exposure to the ...

U.S. drugmaker Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter profit and revenue on Thursday, driven ...

Eli Lilly’s Ebglyss (lebrikizumab-lbkz) showed improvement in skin clearance and itch relief for most patients with ...

and itch among patients with moderate-to-severe atopic dermatitis (eczema) who were previously treated with Sanofi SA (NASDAQ:SNY) / Regeneron Pharmaceuticals Inc’s (NASDAQ:REGN) Dupixent ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.

After years of limited advancements in chronic obstructive pulmonary disease (COPD) treatment, patients now have new options.

Approval based on Phase 3 data showing significantly more children aged 1 to 11 years on Dupixent achieved histological ... research continues and offers new treatment options to improve the ...

Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm ...

with moderate-to-severe atopic dermatitis (eczema) that is not well controlled despite treatment with topical prescription therapies. Ebglyss was also approved in the European Union in 2023 and ...